CeriBell (NASDAQ:CBLL) Price Target Cut to $17.00 by Analysts at JPMorgan Chase & Co.

CeriBell (NASDAQ:CBLL) had its target price decreased by JPMorgan Chase & Co. from $21.00 to $17.00 in a research note issued to investors on Wednesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities research analysts have also weighed in on CBLL. TD Cowen decreased their price objective on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. Finally, Raymond James Financial assumed coverage on shares of CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and an average price target of $25.17.

CeriBell Price Performance

CeriBell stock opened at $11.78 on Wednesday. The firm has a 50-day moving average price of $12.07 and a 200-day moving average price of $14.60. The firm has a market capitalization of $431.90 million and a PE ratio of -7.80. The company has a current ratio of 13.31, a quick ratio of 12.91 and a debt-to-equity ratio of 0.11. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.06. The firm had revenue of $22.59 million during the quarter, compared to analyst estimates of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 28.92%. CeriBell has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that CeriBell will post -2.46 EPS for the current year.

Insider Transactions at CeriBell

In other CeriBell news, CTO Raymond Woo sold 11,112 shares of CeriBell stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $12.54, for a total transaction of $139,344.48. Following the completion of the sale, the chief technology officer directly owned 167,704 shares in the company, valued at approximately $2,103,008.16. The trade was a 6.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 20.10% of the company’s stock.

Hedge Funds Weigh In On CeriBell

Large investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in shares of CeriBell in the 1st quarter valued at $36,000. Tower Research Capital LLC TRC lifted its stake in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the period. Ameritas Investment Partners Inc. lifted its stake in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the period. New York State Common Retirement Fund acquired a new position in shares of CeriBell in the 1st quarter valued at $67,000. Finally, Police & Firemen s Retirement System of New Jersey raised its position in CeriBell by 161.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after acquiring an additional 3,502 shares during the period.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.